LC‑MS‑based HCP analysis is becoming highly relevant across both biology and biotechnology because it provides detailed, protein‑level insight rather than a single aggregate value.

In biotech, it is widely used to support biopharmaceutical development, monitor purification, and demonstrate control of impurities for regulatory purposes. In biology, it underpins advanced proteomics studies, such as understanding cellular pathways or identifying biomarkers.

Thomas Kofoed, PhD, CEO of Alphalyse in Denmark, discussed key factors in implementing GMP-compatible LC-MS methods for release assays and highlighted successful cases where this approach has replaced traditional ELISA methods. Don’t miss his presentation and expert insights at the panel discussion.